يعرض 1 - 10 نتائج من 20 نتيجة بحث عن '"Caroline Robert"', وقت الاستعلام: 0.80s تنقيح النتائج
  1. 1
    Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting

    المؤلفون: Caroline Robert, Hugo Herrscher

    المصدر: Current Opinion in Oncology. 32:106-113

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Ipilimumab, Pembrolizumab, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, Melanoma, Neoadjuvant therapy, Randomized Controlled Trials as Topic, business.industry, Cancer, Immunotherapy, medicine.disease, Neoadjuvant Therapy, 030104 developmental biology, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Nivolumab, business, Adjuvant, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b215dfbe48092e82af5944056d7b08dTest
    https://doi.org/10.1097/cco.0000000000000610Test


    أضف إلى المفضلة
  2. 2
    Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

    المؤلفون: Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan

    المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology

    المصدر: Journal of Clinical Oncology, 38, 3925-3936
    Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
    Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
    Journal of Clinical Oncology
    Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
    Journal of Clinical Oncology, 38, 33, pp. 3925-3936

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
    https://hdl.handle.net/2066/228545Test


    أضف إلى المفضلة
  3. 3
    Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

    المؤلفون: Adil Daud, Jeffrey S. Weber, Georgina V. Long, Matteo S. Carlino, Jacob Schachter, Wen-Jen Hwu, Peter Hersey, Caroline Robert, Antoni Ribas, Le Min, Nageatte Ibrahim, Celine Boutros, Igor Puzanov, Jianxin Lin, Scott J. Diede, F. Stephen Hodi, Reinhard Dummer, Omid Hamid, Richard W. Joseph, Roxana S. Dronca, Jedd D. Wolchok, Tara C. Mitchell, Anthony M. Joshua

    المساهمون: Intégrité du génome, ARN et cancer, Institut Curie [Paris]-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), University of Zurich, Robert, Caroline

    المصدر: European journal of cancer (Oxford, England : 1990)
    European Journal of Cancer
    European Journal of Cancer, Elsevier, 2021, 144, pp.182-191. ⟨10.1016/j.ejca.2020.11.010⟩

    مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, [SDV]Life Sciences [q-bio], Immune-checkpoint inhibitors, Pembrolizumab, Gastroenterology, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immune-related adverse events, Monoclonal, 80 and over, 1306 Cancer Research, Melanoma, Humanized, Cancer, Aged, 80 and over, Clinical Trials as Topic, 10177 Dermatology Clinic, Middle Aged, Prognosis, Advanced melanoma, 3. Good health, Immunological, Oncology, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Toxicity, Public Health and Health Services, 2730 Oncology, Female, PD-1 inhibitors, Adult, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Oncology and Carcinogenesis, 610 Medicine & health, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Article, Antibodies, Vaccine Related, 03 medical and health sciences, Young Adult, Meta-Analysis as Topic, Internal medicine, medicine, Humans, In patient, Oncology & Carcinogenesis, Adverse effect, Pneumonitis, Aged, Immunomodulating drugs, business.industry, Evaluation of treatments and therapeutic interventions, medicine.disease, Clinical trial, 030104 developmental biology, Corticosteroid use, Immunization, business, Follow-Up Studies

    وصف الملف: application/pdf; 868_Robert_C._et_al._Long-term_safety_of_pembrolizumab_monotherapy_and_relationship_with_clinical_outcome_EJC_2020.pdf - application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c081e1b4e51d5ab8b097204bced3e77dTest
    https://escholarship.org/uc/item/275859csTest


    أضف إلى المفضلة
  4. 4
    Post-shingles granulomatous dermatosis related to anti-programmed cell death 1

    المؤلفون: Vincent Ribrag, Jean-Marie Michot, Tony Ibrahim, Peggy Dartigues, David Ghez, Julien Lazarovici, Tarek Assi, Caroline Robert, Christine Mateus, Marie Terroir-Cassou-Mounat, Julien Rossignol, Alina Danu

    المصدر: Immunotherapy. 11:591-598

    مصطلحات موضوعية: 0301 basic medicine, Herpesvirus 3, Human, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Immune checkpoint inhibitors, Immunology, Pembrolizumab, Antibodies, Monoclonal, Humanized, Herpes Zoster, Skin Diseases, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Programmed cell death 1, Dermatomal, Humans, Immunology and Allergy, Medicine, Adverse effect, Neoplasm Staging, Skin, Granuloma, biology, business.industry, Remission Induction, Cancer, Middle Aged, medicine.disease, Hodgkin Disease, Magnetic Resonance Imaging, Dermatology, Stage IV Hodgkin Lymphoma, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Female, Immunotherapy, Tomography, X-Ray Computed, business, Shingles

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57337d95d1038366e184dcaf5976de42Test
    https://doi.org/10.2217/imt-2018-0169Test


    أضف إلى المفضلة
  5. 5
    Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

    المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser

    المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

    المصدر: Ann Transl Med
    European Journal of Cancer, 116, pp. 148-157
    European Journal of Cancer, 116, 148-157. Pergamon
    Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
    European Journal of Cancer, 116, 148-157

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
    https://hdl.handle.net/2066/206244Test


    أضف إلى المفضلة
  6. 6
    Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

    المؤلفون: Caroline Robert, Pablo Cerezuela-Fuentes, Stéphane Dalle, Brigitte Dréno, Miguel Fernández de Sanmamed Gutiérrez, Luis Merino, Vanesa Pons Sanz, Maria Gonzalez Cao, Alfonso Berrocal, Marisol Quintero, Juan Francisco Rodriguez-Moreno, Javier Sánchez-López, Ana Arance, Juana Oramas, Pilar Lopez Criado, Julie Charles, Sofía España, Philippe Saiag, María Rojas, Eduardo Castanon, Helena Escuin-Ordinas, Henri Montaudié, Sonia Maciá, Ivan Marquez-Rodas, Caroline Dutriaux

    المصدر: Cancer Research. 81:CT233-CT233

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Melanoma, Mucosal melanoma, Cancer, Pembrolizumab, medicine.disease, Internal medicine, medicine, Immunogenic cell death, Nivolumab, business, CD8, Progressive disease

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9e9eb08af652def9008252a5262ad131Test
    https://doi.org/10.1158/1538-7445.am2021-ct233Test


    أضف إلى المفضلة
  7. 7
    Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

    المؤلفون: Franck Carbonnel, Emilie Soularue, Christine Mateus, Caroline Robert, Patricia Lepage, Clélia Coutzac, Nathalie Chaput

    المساهمون: Department of Gastroenterology, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris Sud (Paris 11), Laboratoire d’Immunomonitoring en Oncologie (LIO), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), US23 Institut de recherche intégrée en cancérologie, Institut National de la Santé et de la Recherche Médicale (INSERM), Faculté de pharmacie, Université catholique du Graben, Service de dermatologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Université Paris-Saclay

    المصدر: Seminars in Immunopathology
    Seminars in Immunopathology, Springer Verlag, 2017, 39 (3), pp.327-331. ⟨10.1007/s00281-016-0613-x⟩

    مصطلحات موضوعية: 0301 basic medicine, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Immunology, chemical and pharmacologic phenomena, Ipilimumab, Pembrolizumab, Gut flora, Inflammatory bowel disease, Immunomodulation, 03 medical and health sciences, 0302 clinical medicine, Cancer immunotherapy, Neoplasms, medicine, Humans, Immunology and Allergy, CTLA-4 Antigen, Molecular Targeted Therapy, Intestinal Mucosa, Enterocolitis, biology, business.industry, Antibodies, Monoclonal, Cancer, Colitis, Inflammatory Bowel Diseases, medicine.disease, biology.organism_classification, 3. Good health, Intestines, 030104 developmental biology, 030220 oncology & carcinogenesis, Immunotherapy, medicine.symptom, Nivolumab, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::612bda045501f32f49e2138f12fc67ebTest
    https://doi.org/10.1007/s00281-016-0613-xTest


    أضف إلى المفضلة
  8. 8
    Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

    المؤلفون: Christian U. Blank, Scot Ebbinghaus, Reinhard Dummer, Carmen Loquai, Steven J. O'Day, Antoni Ribas, Adil Daud, Jacob Schachter, Caroline Robert, Janice M. Mehnert, Dirk Schadendorf, S. Peter Kang, Wei Zhou, Igor Puzanov, Darcy A. Hille, April K.S. Salama, Omid Hamid, Lee D. Cranmer, Alfons J.M. van den Eertwegh, Axel Hauschild

    المساهمون: University of Zurich, Schadendorf, Dirk, Medical oncology, CCA - Clinical Therapy Development

    المصدر: Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, J M, Hille, D, Ebbinghaus, S, Kang, S P, Zhou, W & Ribas, A 2016, ' Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma ', European Journal of Cancer, vol. 67, pp. 46-54 . https://doi.org/10.1016/j.ejca.2016.07.018Test
    European Journal of Cancer, 67, 46-54. Pergamon

    مصطلحات موضوعية: Male, Cancer Research, Skin Neoplasms, Health Status, Health-related quality of life, medicine.medical_treatment, Medizin, Pembrolizumab, Carboplatin, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, 030212 general & internal medicine, Melanoma, Aged, 80 and over, 10177 Dermatology Clinic, Middle Aged, Advanced melanoma, Dacarbazine, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, medicine.drug, Adult, KEYNOTE-002, medicine.medical_specialty, Adolescent, Paclitaxel, 610 Medicine & health, Ipilimumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Young Adult, 03 medical and health sciences, Refractory, Internal medicine, Temozolomide, medicine, Humans, Chemotherapy, In patient, Patient Reported Outcome Measures, Aged, Patient-reported outcomes, business.industry, Cancer, EORTC QLQ-C30, medicine.disease, Surgery, Quality of Life, business, Ipilimumab-refractory melanoma

    وصف الملف: 663_Schadendorf D. et al._Health-related quality of life in the randomised KEYNOTE-002_EJC 2016.pdf - application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0340a48931fc5ff52f9246c04eeed519Test
    https://doi.org/10.1016/j.ejca.2016.07.018Test


    أضف إلى المفضلة
  9. 9
    Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

    المؤلفون: Nageatte Ibrahim, Richard W. Joseph, Caroline Robert, Roxana S. Dronca, Adil Daud, Tara C. Mitchell, Jedd D. Wolchok, Omid Hamid, Richard F. Kefford, Jeffrey S. Weber, Antoni Ribas, Qing Zhao, Erin Jensen, Amita Patnaik, Anthony M. Joshua, F.S. Hodi, W. Hwu, Peter Hersey, Hassane M. Zarour, Sama Ahsan

    المصدر: Annals of oncology : official journal of the European Society for Medical Oncology, vol 30, iss 4
    Annals of Oncology

    مصطلحات موضوعية: 0301 basic medicine, Skin Neoplasms, long-term follow-up, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, Monoclonal, Humanized, Melanoma, Cancer, treatment-naive, Hematology, metastatic, Immunological, Oncology, Tolerability, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, pembrolizumab, Adult, medicine.medical_specialty, Patients, overall survival, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Antibodies, Drug Administration Schedule, Time, Vaccine Related, 03 medical and health sciences, Clinical Research, Internal medicine, medicine, Overall survival, melanoma, Humans, Oncology & Carcinogenesis, Until Disease Progression, Response Evaluation Criteria in Solid Tumors, Advanced melanoma, business.industry, Evaluation of treatments and therapeutic interventions, Original Articles, medicine.disease, Discontinuation, Clinical trial, Editor's Choice, 030104 developmental biology, business, Follow-Up Studies

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4525cdc4a9d2f1fea9bc8b0ee243f7Test
    https://pubmed.ncbi.nlm.nih.gov/30768148Test


    أضف إلى المفضلة
  10. 10
    Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

    المؤلفون: Adil Daud, Jeroen Elassaiss-Schaap, Richard F. Kefford, Jin Zhang, Jeffrey S. Weber, Andrea Marie Perrone, Amita Patnaik, Caroline Robert, F. Stephen Hodi, Peter Hersey, Wen-Jen Hwu, Antoni Ribas, Richard W. Joseph, Jedd D. Wolchok, Tara C. Gangadhar, Omid Hamid, S. Peter Kang, Dinesh P. de Alwis, Roxana S. Dronca, Anthony M. Joshua, Keaven M. Anderson, Scot Ebbinghaus

    المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 20
    Clinical Cancer Research
    Clinical Cancer Research, 24(20), 4960–4967

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, Skin Neoplasms, Oncology and Carcinogenesis, Pembrolizumab, Logistic regression, Antibodies, Monoclonal, Humanized, Article, 03 medical and health sciences, 0302 clinical medicine, Clinical Research, Internal medicine, Post-hoc analysis, Biomarkers, Tumor, Medicine, Humans, Oncology & Carcinogenesis, Melanoma, Cancer, Univariate analysis, L-Lactate Dehydrogenase, Proportional hazards model, business.industry, Hazard ratio, medicine.disease, Prognosis, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, business

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5259ec95070357aaab6d85752cf2a5Test
    https://escholarship.org/uc/item/62m363dnTest


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث